Functional Plasminogen Activator Inhibitor-1 Gene Variants and Breast Cancer Survival
Purpose: Plasminogen activator inhibitor-1 (PAI-1) plays an important role in cancer invasion and metastasis. A common polymorphism (4G/5G) in the promoter region of the PAI-1 gene has been reported to influence transcription and plasma levels of PAI-1. We evaluated the association between PAI-1 4G/...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2006-10, Vol.12 (20), p.6037-6042 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6042 |
|---|---|
| container_issue | 20 |
| container_start_page | 6037 |
| container_title | Clinical cancer research |
| container_volume | 12 |
| creator | Zhang, Xianglan Shu, Xiao-Ou Cai, Qiuyin Ruan, ZhiXian Gao, Yu-Tang Zheng, Wei |
| description | Purpose: Plasminogen activator inhibitor-1 (PAI-1) plays an important role in cancer invasion and metastasis. A common polymorphism
(4G/5G) in the promoter region of the PAI-1 gene has been reported to influence transcription and plasma levels of PAI-1. We evaluated the association between PAI-1 4G/5G polymorphism and breast cancer survival in a population-based cohort of breast cancer patients.
Experimental Design: Included in this analysis were 1,083 Chinese women diagnosed with stage 0 to III primary breast cancer at age 25 to 64 years
who were recruited between 1996 and 1998 for the Shanghai Breast Cancer Study and followed for a median of 5.2 years. The
Kaplan-Meier method and Cox model were used to evaluate the genotype and survival association.
Results: After adjustment for known prognostic factors for breast cancer, patients homozygous for the 4G allele had significantly
poorer disease-free survival [hazard ratio (HR), 1.7; 95% confidence interval (95% CI), 1.1-2.4] and overall survival (HR,
1.5; 95% CI, 1.0-2.3) than those homozygous for the 5G allele. The association was more evident in patients with advanced
disease. The HRs (95% CI) were 3.5 (1.4-9.0) for disease-free survival and 3.1 (1.1-8.3) for overall survival in stage III
patients.
Conclusions: The PAI-1 4G/5G polymorphism may be a prognostic marker for young and middle-aged Chinese breast cancer patients. |
| doi_str_mv | 10.1158/1078-0432.CCR-05-2851 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68986479</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20852203</sourcerecordid><originalsourceid>FETCH-LOGICAL-c402t-61ec7dbae032a0d930a35448bb32f54c899606726f0bfe7b5a65e581eea30e0d3</originalsourceid><addsrcrecordid>eNqFkE1v1DAQhiMEoqXwE0C-gMQhZWzHHzmWqC2VKhXxdbUmzqRrlHWKnRT13-NlF_XIaUaj550ZPVX1msMp58p-4GBsDY0Up133pQZVC6v4k-qYK2VqKbR6Wvp_zFH1IuefALzh0DyvjrgBLbSxx9X3izX6JcwRJ_Z5wrwNcb6lyM7K8B6XObGruAl9KF3N2SVFYj8wBYxLZhgH9jER5oV1GD0l9nVN9yU2vayejThlenWoJ-XO-bfuU319c3nVnV3XvgGx1JqTN0OPBFIgDK0ElKppbN9LMarG27bVoI3QI_QjmV6hVqQsJ0IJBIM8qd7t996l-ddKeXHbkD1NE0aa1-y0ba1uTPtfUIBVQoAsoNqDPs05JxrdXQpbTA-Og9uJdzupbifVFfEOlNuJL7k3hwNrv6XhMXUwXYC3BwCzx2lMxVjIj5wVojVGFe79ntuE283vkMj5v24TZcLkN46L8q3TII38AyuqmVs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20852203</pqid></control><display><type>article</type><title>Functional Plasminogen Activator Inhibitor-1 Gene Variants and Breast Cancer Survival</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Zhang, Xianglan ; Shu, Xiao-Ou ; Cai, Qiuyin ; Ruan, ZhiXian ; Gao, Yu-Tang ; Zheng, Wei</creator><creatorcontrib>Zhang, Xianglan ; Shu, Xiao-Ou ; Cai, Qiuyin ; Ruan, ZhiXian ; Gao, Yu-Tang ; Zheng, Wei</creatorcontrib><description>Purpose: Plasminogen activator inhibitor-1 (PAI-1) plays an important role in cancer invasion and metastasis. A common polymorphism
(4G/5G) in the promoter region of the PAI-1 gene has been reported to influence transcription and plasma levels of PAI-1. We evaluated the association between PAI-1 4G/5G polymorphism and breast cancer survival in a population-based cohort of breast cancer patients.
Experimental Design: Included in this analysis were 1,083 Chinese women diagnosed with stage 0 to III primary breast cancer at age 25 to 64 years
who were recruited between 1996 and 1998 for the Shanghai Breast Cancer Study and followed for a median of 5.2 years. The
Kaplan-Meier method and Cox model were used to evaluate the genotype and survival association.
Results: After adjustment for known prognostic factors for breast cancer, patients homozygous for the 4G allele had significantly
poorer disease-free survival [hazard ratio (HR), 1.7; 95% confidence interval (95% CI), 1.1-2.4] and overall survival (HR,
1.5; 95% CI, 1.0-2.3) than those homozygous for the 5G allele. The association was more evident in patients with advanced
disease. The HRs (95% CI) were 3.5 (1.4-9.0) for disease-free survival and 3.1 (1.1-8.3) for overall survival in stage III
patients.
Conclusions: The PAI-1 4G/5G polymorphism may be a prognostic marker for young and middle-aged Chinese breast cancer patients.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-05-2851</identifier><identifier>PMID: 17062678</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Antineoplastic agents ; Biological and medical sciences ; breast cancer survival ; Breast Neoplasms - epidemiology ; Breast Neoplasms - genetics ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; China - epidemiology ; Female ; gene ; Genetic Markers ; Genetic Variation ; Gynecology. Andrology. Obstetrics ; Humans ; Mammary gland diseases ; Medical sciences ; Neoplasm Invasiveness ; Neoplasm Metastasis ; PAI-1 ; Pharmacology. Drug treatments ; Plasminogen Activator Inhibitor 1 - genetics ; polymorphism ; Prognosis ; Registries ; Survival Analysis ; Tumors</subject><ispartof>Clinical cancer research, 2006-10, Vol.12 (20), p.6037-6042</ispartof><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c402t-61ec7dbae032a0d930a35448bb32f54c899606726f0bfe7b5a65e581eea30e0d3</citedby><cites>FETCH-LOGICAL-c402t-61ec7dbae032a0d930a35448bb32f54c899606726f0bfe7b5a65e581eea30e0d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,3357,27929,27930</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18229775$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17062678$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Xianglan</creatorcontrib><creatorcontrib>Shu, Xiao-Ou</creatorcontrib><creatorcontrib>Cai, Qiuyin</creatorcontrib><creatorcontrib>Ruan, ZhiXian</creatorcontrib><creatorcontrib>Gao, Yu-Tang</creatorcontrib><creatorcontrib>Zheng, Wei</creatorcontrib><title>Functional Plasminogen Activator Inhibitor-1 Gene Variants and Breast Cancer Survival</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Purpose: Plasminogen activator inhibitor-1 (PAI-1) plays an important role in cancer invasion and metastasis. A common polymorphism
(4G/5G) in the promoter region of the PAI-1 gene has been reported to influence transcription and plasma levels of PAI-1. We evaluated the association between PAI-1 4G/5G polymorphism and breast cancer survival in a population-based cohort of breast cancer patients.
Experimental Design: Included in this analysis were 1,083 Chinese women diagnosed with stage 0 to III primary breast cancer at age 25 to 64 years
who were recruited between 1996 and 1998 for the Shanghai Breast Cancer Study and followed for a median of 5.2 years. The
Kaplan-Meier method and Cox model were used to evaluate the genotype and survival association.
Results: After adjustment for known prognostic factors for breast cancer, patients homozygous for the 4G allele had significantly
poorer disease-free survival [hazard ratio (HR), 1.7; 95% confidence interval (95% CI), 1.1-2.4] and overall survival (HR,
1.5; 95% CI, 1.0-2.3) than those homozygous for the 5G allele. The association was more evident in patients with advanced
disease. The HRs (95% CI) were 3.5 (1.4-9.0) for disease-free survival and 3.1 (1.1-8.3) for overall survival in stage III
patients.
Conclusions: The PAI-1 4G/5G polymorphism may be a prognostic marker for young and middle-aged Chinese breast cancer patients.</description><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>breast cancer survival</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>China - epidemiology</subject><subject>Female</subject><subject>gene</subject><subject>Genetic Markers</subject><subject>Genetic Variation</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Neoplasm Invasiveness</subject><subject>Neoplasm Metastasis</subject><subject>PAI-1</subject><subject>Pharmacology. Drug treatments</subject><subject>Plasminogen Activator Inhibitor 1 - genetics</subject><subject>polymorphism</subject><subject>Prognosis</subject><subject>Registries</subject><subject>Survival Analysis</subject><subject>Tumors</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1v1DAQhiMEoqXwE0C-gMQhZWzHHzmWqC2VKhXxdbUmzqRrlHWKnRT13-NlF_XIaUaj550ZPVX1msMp58p-4GBsDY0Up133pQZVC6v4k-qYK2VqKbR6Wvp_zFH1IuefALzh0DyvjrgBLbSxx9X3izX6JcwRJ_Z5wrwNcb6lyM7K8B6XObGruAl9KF3N2SVFYj8wBYxLZhgH9jER5oV1GD0l9nVN9yU2vayejThlenWoJ-XO-bfuU319c3nVnV3XvgGx1JqTN0OPBFIgDK0ElKppbN9LMarG27bVoI3QI_QjmV6hVqQsJ0IJBIM8qd7t996l-ddKeXHbkD1NE0aa1-y0ba1uTPtfUIBVQoAsoNqDPs05JxrdXQpbTA-Og9uJdzupbifVFfEOlNuJL7k3hwNrv6XhMXUwXYC3BwCzx2lMxVjIj5wVojVGFe79ntuE283vkMj5v24TZcLkN46L8q3TII38AyuqmVs</recordid><startdate>20061015</startdate><enddate>20061015</enddate><creator>Zhang, Xianglan</creator><creator>Shu, Xiao-Ou</creator><creator>Cai, Qiuyin</creator><creator>Ruan, ZhiXian</creator><creator>Gao, Yu-Tang</creator><creator>Zheng, Wei</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20061015</creationdate><title>Functional Plasminogen Activator Inhibitor-1 Gene Variants and Breast Cancer Survival</title><author>Zhang, Xianglan ; Shu, Xiao-Ou ; Cai, Qiuyin ; Ruan, ZhiXian ; Gao, Yu-Tang ; Zheng, Wei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c402t-61ec7dbae032a0d930a35448bb32f54c899606726f0bfe7b5a65e581eea30e0d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>breast cancer survival</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>China - epidemiology</topic><topic>Female</topic><topic>gene</topic><topic>Genetic Markers</topic><topic>Genetic Variation</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Neoplasm Invasiveness</topic><topic>Neoplasm Metastasis</topic><topic>PAI-1</topic><topic>Pharmacology. Drug treatments</topic><topic>Plasminogen Activator Inhibitor 1 - genetics</topic><topic>polymorphism</topic><topic>Prognosis</topic><topic>Registries</topic><topic>Survival Analysis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Xianglan</creatorcontrib><creatorcontrib>Shu, Xiao-Ou</creatorcontrib><creatorcontrib>Cai, Qiuyin</creatorcontrib><creatorcontrib>Ruan, ZhiXian</creatorcontrib><creatorcontrib>Gao, Yu-Tang</creatorcontrib><creatorcontrib>Zheng, Wei</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Xianglan</au><au>Shu, Xiao-Ou</au><au>Cai, Qiuyin</au><au>Ruan, ZhiXian</au><au>Gao, Yu-Tang</au><au>Zheng, Wei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Functional Plasminogen Activator Inhibitor-1 Gene Variants and Breast Cancer Survival</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2006-10-15</date><risdate>2006</risdate><volume>12</volume><issue>20</issue><spage>6037</spage><epage>6042</epage><pages>6037-6042</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Purpose: Plasminogen activator inhibitor-1 (PAI-1) plays an important role in cancer invasion and metastasis. A common polymorphism
(4G/5G) in the promoter region of the PAI-1 gene has been reported to influence transcription and plasma levels of PAI-1. We evaluated the association between PAI-1 4G/5G polymorphism and breast cancer survival in a population-based cohort of breast cancer patients.
Experimental Design: Included in this analysis were 1,083 Chinese women diagnosed with stage 0 to III primary breast cancer at age 25 to 64 years
who were recruited between 1996 and 1998 for the Shanghai Breast Cancer Study and followed for a median of 5.2 years. The
Kaplan-Meier method and Cox model were used to evaluate the genotype and survival association.
Results: After adjustment for known prognostic factors for breast cancer, patients homozygous for the 4G allele had significantly
poorer disease-free survival [hazard ratio (HR), 1.7; 95% confidence interval (95% CI), 1.1-2.4] and overall survival (HR,
1.5; 95% CI, 1.0-2.3) than those homozygous for the 5G allele. The association was more evident in patients with advanced
disease. The HRs (95% CI) were 3.5 (1.4-9.0) for disease-free survival and 3.1 (1.1-8.3) for overall survival in stage III
patients.
Conclusions: The PAI-1 4G/5G polymorphism may be a prognostic marker for young and middle-aged Chinese breast cancer patients.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>17062678</pmid><doi>10.1158/1078-0432.CCR-05-2851</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2006-10, Vol.12 (20), p.6037-6042 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68986479 |
| source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Antineoplastic agents Biological and medical sciences breast cancer survival Breast Neoplasms - epidemiology Breast Neoplasms - genetics Breast Neoplasms - mortality Breast Neoplasms - pathology China - epidemiology Female gene Genetic Markers Genetic Variation Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Medical sciences Neoplasm Invasiveness Neoplasm Metastasis PAI-1 Pharmacology. Drug treatments Plasminogen Activator Inhibitor 1 - genetics polymorphism Prognosis Registries Survival Analysis Tumors |
| title | Functional Plasminogen Activator Inhibitor-1 Gene Variants and Breast Cancer Survival |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T06%3A31%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Functional%20Plasminogen%20Activator%20Inhibitor-1%20Gene%20Variants%20and%20Breast%20Cancer%20Survival&rft.jtitle=Clinical%20cancer%20research&rft.au=Zhang,%20Xianglan&rft.date=2006-10-15&rft.volume=12&rft.issue=20&rft.spage=6037&rft.epage=6042&rft.pages=6037-6042&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-05-2851&rft_dat=%3Cproquest_cross%3E20852203%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20852203&rft_id=info:pmid/17062678&rfr_iscdi=true |